Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Paraneoplastic neurological syndrome as an initial indicator of small cell carcinoma of the lung.

BMJ case reports

Porto L, Miranda M, Gomes A, André R, Rodrigues B.
PMID: 23391962
BMJ Case Rep. 2013 Feb 06;2013. doi: 10.1136/bcr-2012-008432.

Paraneoplastic syndromes are indirect manifestations of cancer due to functional peptides/hormones produced by a tumour, or due to cross reactivity between tumour and host antigens. Here the case of a 58-year-old woman presenting with ataxia, paraesthesia and subacute and...

Cite
Porto L, Miranda M, Gomes A, et al. Paraneoplastic neurological syndrome as an initial indicator of small cell carcinoma of the lung. BMJ Case Rep. 2013;2013doi: 10.1136/bcr-2012-008432.
Porto, L., Miranda, M., Gomes, A., André, R., & Rodrigues, B. (2013). Paraneoplastic neurological syndrome as an initial indicator of small cell carcinoma of the lung. BMJ case reports, 2013. https://doi.org/10.1136/bcr-2012-008432
Porto, Lénea, et al. "Paraneoplastic neurological syndrome as an initial indicator of small cell carcinoma of the lung." BMJ case reports vol. 2013 (2013). doi: https://doi.org/10.1136/bcr-2012-008432
Porto L, Miranda M, Gomes A, André R, Rodrigues B. Paraneoplastic neurological syndrome as an initial indicator of small cell carcinoma of the lung. BMJ Case Rep. 2013 Feb 06;2013. doi: 10.1136/bcr-2012-008432. PMID: 23391962; PMCID: PMC3603971.
Copy Download .nbib Format: NLM
[Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer].

Zhongguo fei ai za zhi = Chinese journal of lung cancer

Huang B, Duan Y.
PMID: 31014443
Zhongguo Fei Ai Za Zhi. 2019 Apr 20;22(4):239-244. doi: 10.3779/j.issn.1009-3419.2019.04.07.

With the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis...

Cite
Huang B, Duan Y. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2019;22(4):239-244doi: 10.3779/j.issn.1009-3419.2019.04.07.
Huang, B., & Duan, Y. (2019). [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 22(4), 239-244. https://doi.org/10.3779/j.issn.1009-3419.2019.04.07
Huang, Benlin, and Duan, Yong. "[Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]." Zhongguo fei ai za zhi = Chinese journal of lung cancer vol. 22,4 (2019): 239-244. doi: https://doi.org/10.3779/j.issn.1009-3419.2019.04.07
Huang B, Duan Y. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2019 Apr 20;22(4):239-244. doi: 10.3779/j.issn.1009-3419.2019.04.07. Chinese. PMID: 31014443; PMCID: PMC6500500.
Copy Download .nbib Format: NLM
Cancer and immunosurveillance.

Lancet (London, England)

MacGregor GA.
PMID: 4123571
Lancet. 1973 May 26;1(7813):1185. doi: 10.1016/s0140-6736(73)91184-7.

No abstract available.

Cite
MacGregor GA. Cancer and immunosurveillance. Lancet. 1973;1(7813):1185doi: 10.1016/s0140-6736(73)91184-7.
MacGregor, G. A. (1973). Cancer and immunosurveillance. Lancet (London, England), 1(7813), 1185. https://doi.org/10.1016/s0140-6736(73)91184-7
MacGregor, G A. "Cancer and immunosurveillance." Lancet (London, England) vol. 1,7813 (1973): 1185. doi: https://doi.org/10.1016/s0140-6736(73)91184-7
MacGregor GA. Cancer and immunosurveillance. Lancet. 1973 May 26;1(7813):1185. doi: 10.1016/s0140-6736(73)91184-7. PMID: 4123571.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries